These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11464134)

  • 1. Cavernositis following intracavernous injection of vasoactive drugs.
    Vives A; Collado A; Ribé N; Segarra J; Ruiz Castañé E; Pomerol JM
    Urol Int; 2001; 67(1):111-2. PubMed ID: 11464134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penile shaft hypopigmentation: lichen sclerosus occurring after the initiation of alprostadil intracavernous injections for erectile dysfunction.
    English JC; King DH; Foley JP
    J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):801-3. PubMed ID: 9810901
    [No Abstract]   [Full Text] [Related]  

  • 3. Early treatment of cavernositis resulted in erectile function preservation.
    Shamloul R; Kamel I
    J Sex Med; 2006 Mar; 3(2):320-2. PubMed ID: 16490026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracavernous injection as an option for aging men with erectile dysfunction.
    Wespes E
    Aging Male; 2002 Sep; 5(3):177-80. PubMed ID: 12471778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
    Tang SF; Chu NK; Wong MK
    Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intracavernous injection of vasoactive agents].
    Kawanishi Y
    Nihon Rinsho; 2002 Jun; 60 Suppl 6():285-9. PubMed ID: 12166159
    [No Abstract]   [Full Text] [Related]  

  • 8. [Patient response to and assessment of intracavernous drug injection and vacuum].
    Vives Suñé A; Ribé Subirá N; Manasia P; Pomerol Monseny JM
    Actas Urol Esp; 2000 Mar; 24(3):231-4. PubMed ID: 10870230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
    Linet OI; Ogrinc FG
    N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The opinion of patients treated with intracavernous injections: the EASY survey].
    Desvaux P; Alexandre B
    Presse Med; 2005 Jul; 34(13 Suppl):10-2. PubMed ID: 16158022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial.
    Montorsi F; Guazzoni G; Strambi LF; Da Pozzo LF; Nava L; Barbieri L; Rigatti P; Pizzini G; Miani A
    J Urol; 1997 Oct; 158(4):1408-10. PubMed ID: 9302132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial infarction associated with intra-cavernosal administration of alprostadil in a patient with spinal cord injury and paraplegia.
    Vaidyanathan S; Krishnan KR
    Spinal Cord; 1996 Dec; 34(12):754-5. PubMed ID: 8961437
    [No Abstract]   [Full Text] [Related]  

  • 14. Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy.
    Yiou R; Cunin P; de la Taille A; Salomon L; Binhas M; Lingombet O; Paul M; Abbou C
    J Sex Med; 2011 Feb; 8(2):575-82. PubMed ID: 20807323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group B streptococcal septicemia following intracavernous injection therapy for erectile dysfunction in diabetes.
    Nalesnik JG; Jones L; Kraus SR
    J Urol; 2004 Jul; 172(1):151-2. PubMed ID: 15201758
    [No Abstract]   [Full Text] [Related]  

  • 16. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.
    Polito M; d'Anzeo G; Conti A; Muzzonigro G
    BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transurethral alprostadil (MUSE) in erectile dysfunction].
    Comeri G; Gianneo E; Nespoli R
    Arch Ital Urol Androl; 1999 Sep; 71(4):249-51. PubMed ID: 10592541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracorporeal needle breakage as an unusual complication of intracavernous self-injection.
    Iacono F; Barra S
    Tech Urol; 1998 Mar; 4(1):54-5. PubMed ID: 9568779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of organic erectile dysfunction.
    Kim ED; Lipshultz LI
    Hosp Pract (1995); 1997 Apr; 32(4):101-4, 107-8, 113-4 passim. PubMed ID: 9109810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term results of the treatment with intracavernous injection of vasoactive drugs].
    Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA
    Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.